Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 7/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1008401 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2KDM4ES1PR5S1PR4S1PR1 | |
| SCHEMBL7459216 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2KDM4ES1PR5S1PR4S1PR1 | |
| SCHEMBL9912438 | 0.88 | KDM4E (0.50) | SMN1; SMN2KDM4EPOLBPKMTSHR | |
| SCHEMBL12635335 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2KDM4EALDH1A1POLBPKM | |
| SCHEMBL12635333 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2KDM4EALDH1A1POLBPKM | |
| SCHEMBL24131518 | 0.78 | MEN1 (0.44) | SMN1; SMN2KDM4ES1PR5S1PR4S1PR1 | |
| SCHEMBL22440366 | 0.78 | MEN1 (0.44) | SMN1; SMN2KDM4ES1PR5S1PR4S1PR1 | |
| SCHEMBL3264345 | 0.78 | CYP1A2 (0.46) | SMN1; SMN2S1PR5S1PR4S1PR1S1PR3 | |
| SCHEMBL29210116 | 0.76 | KDM4E (0.53) | SMN1; SMN2KDM4EALDH1A1GAA | |
| SCHEMBL1006828 | 0.76 | KDM4E (0.45) | SMN1; SMN2KDM4EALDH1A1POLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105488-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | CHLORION PHARMA, INC. (CA) | 2011-05-05 | — | — | US | claimed |
| EP-2268616-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | Chlorion Pharma, Inc. (CA) | 2011-01-05 | — | — | EP | claimed |
| WO-2009114950-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | CHLORION PHARMA, INC. (CA) | 2009-09-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105488-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | PAM, PNN, NOD1 | SMN1; SMN2 1184/4885KDM4E 1799/4885S1PR5 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.